

AMENDMENTS TO THE CLAIMS

1. **(Currently Amended)** A pharmaceutical preparation comprising a synergistic combination of abacavir and alovudine and a pharmaceutical carrier therefore, wherein the alovudine is present in an amount of 0.5-5 mg per unit dose and the abacavir is present in an amount of 300-800 mg per unit dose.
2. **Cancelled**
3. **Cancelled**
4. **Cancelled**
5. **Cancelled**
6. **(Original)** A preparation according to claim 15, wherein the abacavir is present in an amount of 300-500 mg per unit dose.
7. **(Currently Amended)** A preparation according to claim 1, wherein the alovudine and abacavir are present in a weight ratio corresponding to their respective effective dose giving 50% reduction of virus replication (ED50).

8. **Canceled**

9. **(Original)** A patient pack comprising alovudine and/or abacavir and an information insert containing directions on the use of both alovudine and abacavir together in combination.

10. **(Previously Presented)** A method for the treatment of multiresistant HIV in a patient which comprises administering to said patient an effective amount of a synergistic combination of abacavir and alovudine.

11. **(Previously Presented)** The method of claim 10, wherein said administration comprises simultaneous, combined or sequential administration of alovudine and abacavir.

12. **(Previously Presented)** The method of claim 10, wherein the administration comprises administration of the patient pack of claim 9.